The Cardboard Packaging Manufacturer Grupo La Plana Adds Another Purchase

The supplier of cardboard containers and packaging from Castellón, Grupo La Plana, has closed the purchase of 100% of the shares of the company Envases Soler, located in the Alicante town of Crevillente and specialized in the manufacture, design and development of cardboard containers and packaging to measure

Founded in 1959 and of family origin, Envases Soler began its career manufacturing shoe boxes for different shoe factories in Elche, Elda, Alicante and other nearby areas of influence and for other important companies in the toy and textile sector .

In recent years, the company has been expanding its operational scope to new markets, consolidating a wide catalog of different formats of ecological and biodegradable containers and packaging made of corrugated and compact cardboard.

The company from Alicante has specialized in sectors such as the meat and sweets industry, processed food and beverages , and other formats for take away, delivery and street food segments with practical, functional and approved designs that use inks, varnishes, glues and materials. fully suitable for use in food contact packaging.

In addition, Envases Soler also has packaging specifically designed and developed for cosmetic items and parapharmacy products, footwear and accessories in general, and special boxes and cases for toys with special finishes that include accessories also made of cardboard.

Growth with purchases
With facilities of more than 12,000 square meters and a human team of more than 60 professionals, Envases Soler is the sixth production plant to join Grupo La Plana, after the purchase in 2021 of the Madrid company Primera Línea Visual (PLV) , specialized in the manufacture of display solutions at the point of sale.

The operation allows the group to significantly expand its already notable offset packaging manufacturing capacity, which led to the incorporation of Packaging Igualada into the group in 2017.

With this new acquisition, Grupo La Plana exceeds 700 employees and continues to meet the objectives set in its strategic plan for expansion and growth in new markets and geographical areas. A growth that has allowed the Castellón company to exceed 100 million euros in sales.

Grupo La Plana, founded in 1973 by the Piquer Gumbau family, specializes in cardboard packaging solutions and display formats for sectors such as agriculture, food, beverages, fast-moving goods, ceramics and industry. The company has more than 110,000 square meters of facilities, 6 production plants and 14 assembly centers with the capacity to manufacture 500 million square meters of corrugated cardboard per year.

Sánchez Advances A Gas VAT Reduction From 21% To 5% From October

VAT on gas will go from 21% to 5% starting in October. The President of the Government, Pedro Sánchez, has advanced the reduction this Thursday, one more measure in the plan that the Executive is developing in the face of the energy crisis that threatens Europe in the face of winter.

“I announce that the Government is going to propose a drop from 21 to 5 percent of VAT on gas,” Sánchez indicated in Cadena Ser. The measure will be proposed from October to December 31 , although the Executive is open to extend the measure throughout the next year if the situation remains complex.

Sánchez has described as “reasonable” that the Executive try to lower the heating bill to continue “protecting the middle and working class” at a time of so much uncertainty caused by the war in Ukraine. Before this measure, Sánchez recalled, the Government had already reduced taxes linked to electricity by 80% ; VAT is at 5% from June 25.

The reduction of VAT on gas will cost the State around 190 million euros, which it will stop entering in the closing quarter of the year, according to the Minister of Finance and Public Function, María Jesús Montero, in statements to the media. in Mérida, where he met with the president of the Junta de Extremadura, Guillermo Fernández Vara.

It is, he said, a “selective” tax measure for families and companies to save around these almost 200 million euros. According to the calculations advanced by the minister, the reduction in VAT on gas will have a lower impact than on electricity, since by next December the Government will have saved more than 10,000 million euros for families and companies.

The measure will not be without controversy.
The Government takes the step after having requested the PP on several occasions to the Government for this VAT reduction on gas. In fact, it was one of the proposals that the parliamentary group announced that it would formulate at Sánchez’s appearance in the Senate next Tuesday in which he will explain the energy saving measures.

The measure, however, will not be without controversy. Shortly after the announcement, the leader of Más País, Íñigo Errejón, questioned the generalized reduction on Twitter and announced that he would propose to Sánchez “a progressive VAT for gas consumption” to encourage more energy saving and because it is fairer, for not helping equally “those who have little and those who have a lot”.

Regarding Europe’s gas supply problems for winter (despite the fact that reserves are above what was calculated for these dates, they are only enough to cover two months of consumption ), the president has maintained the message in which other members of the Government, such as Vice President Teresa Ribera, have insisted in recent days: the Government is not contemplating gas restrictions for this winter because the situation in Spain is safer than that of other countries despite widespread uncertainty.

Last week, the Executive obtained the approval of Congress for the energy saving plan that aims to deal with the rise in energy prices and dependence on Russia. Among the measures included is the controversial limitation of the temperature in heating (maximum 19 degrees) and air conditioning (minimum 27 degrees).

Europe Takes 18 Months Longer Than US To Approve New Therapies

The first link for a new drug to reach Spain goes through the EMA . However, if the process is already slow in this country, we must add the delay of the European regulatory body in the authorization of new therapeutics: Europe takes an average of two years to approve medicines. When compared to its counterpart in the United States, the situation is very different. The FDA takes a year and a half less to give a technical yes to new therapies than the EMA.

The EMA’s procedures are much more rigid than the FDA’s. This is the main reason for the temporary difference of one organism compared to another. The American agency has accelerated approval mechanisms for drugs against rare diseases and for those that have no cure. In fact, in 2019, it authorized around 60% of the fast-track requests submitted to it.

The European body also has emergency mechanisms, but they are not as flexible as the American ones . During the most critical months of the pandemic, the EMA launched an exceptional instrument (rolling review) to speed up the approval process for vaccines against Covid-19. However, its use does not seem to have been transferred to those diseases where there are no advances in treatment.

Accelerated approval mechanisms constitute the main divergences between one agency and another . “One of the fundamental differences between the EMA and the FDA is manifested in the existence of accelerated approval mechanisms, which are reserved particularly for drugs that may be more effective for incurable diseases or for unknown treatment,” the report states. The European Medicines Agency (EMA): how to overcome mistakes of the past’ prepared by Citizen Europe.

Oncological and hematological drugs are the most authorized by fast track. While twelve drugs for cancer and five for hematological diseases were approved in the United States, the European authorities only approved seven oncological drugs and two related to hematology.

lack of transparency
Transparency is another of the differences that govern both institutions . The proposal criteria for the members of the Board of Directors of the EMA is open, which may cause political criteria or government affinity to be produced. The national component is deeply rooted in the European organization , since the members that make it up are proposed by the Member States.

The situation is very different in the United States, where there are no territorial parameters in the organization of the FDA . “We have to go to a concept of transparency that is supervised by an autonomous body. The agency lacks a common framework for action. The political and territorial component in the FDA is minimal. However, in the EMA, the Cyprus’ vote than that of countries with top-level research centers such as Belgium, France or the Netherlands”, explains José Carlos Cano Montejano, president of Europa Ciudadana.

These issues are collected in the report ‘The European Medicines Agency: how to overcome mistakes of the past’, prepared by Europa Ciudadana, an academic think tank specializing in European Affairs. It highlights the lack of independence in the election of the members of its committees, the lack of transparency in some processes or the slow pace in the approval of new drugs.